CoChat

Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double‐blind, randomized, 1‐year study

Rosenstock, J., Wilson, C., Fleck, P. · 2013 · Diabetes, Obesity and Metabolism
Cited by 86

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Aim: To prospectively evaluate the efficacy and safety of alogliptin versus glipizide in elderly patients with type 2 diabetes mellitus ( T2DM ) over 1 year of treatment. Methods: This was a randomized, double‐blind, active‐controlled study of elderly T2DM patients (aged 65–90 years) with mild hyperglycaemia on diet/exercise therapy alone [glycosylated haemoglobin ( HbA1c ) 6.5–9.0%] or plus oral antidiabetic monotherapy ( HbA1c 6.5–8.0%). Patients were randomized to once‐daily alogliptin 25 mg or glipizide 5 mg titrated to 10 mg, if needed. Hypoglycaemic episodes were systematically captured under predefined criteria. Results: In the primary analysis, HbA1c mean changes from a baseline of 7.5% were −0.14% with alogliptin (n = 222) and −0.09% with glipizide (n = 219) at the end of the study, demonstrating non‐inferiority of alogliptin to glipizide [least squares ( LS ) mean difference = −0.05%; one‐sided 97.5% confidence interval ( CI ): −∞, 0.13%]. More clinically relevant HbA1c reductions occurred among patients who completed the study: −0.42 and −0.33% with alogliptin and glipizide, with non‐inferiority again confirmed ( LS mean difference = −0.09%; one‐sided 97.5% CI : −∞, 0.07%). Overall, alogliptin was safe and well tolerated, with notably fewer hypoglycaemic episodes than glipizide [5.4% (31 episodes) vs. 26.0% (232 episodes), respectively]; three patients experienced severe hypoglycaemia, all with glipizide. Alogliptin also resulted in favourable weight changes versus glipizide (−0.62 vs. 0.60 kg at week 52; p < 0.001). Conclusions: Alogliptin monotherapy maintained glycaemic control comparable to that of glipizide in elderly patients with T2DM over 1 year of treatment, with substantially lower risk of hypoglycaemia and without weight gain.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.12102

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 86

Metadata

Authors
Rosenstock, J., Wilson, C., & Fleck, P.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2013-04-18
Volume
15
Issue
10
Pages
906-914
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W1998735190
Cited by
86
References
4
FWCI
9.20
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.